BioSpace News Archive

CNS Pharmaceuticals, Inc. announced it has appointed Faith L. Charles as Chair of its Board of Directors.

FzioMed, Inc., a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors.

An Extraordinary General Meeting of Nordic Nanovector ASA was held on 3 January 2023 in Oslo, Norway.

Metagenomi today announced that Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

Bresotec Medical (“Bresotec” or the “Company”), a medical device company that develops, manufactures, and markets non-invasive portable diagnostic devices for accurate at-home diagnosis of sleep apnea, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for BresoDX1, its initial product for at-home sleep apnea testing.

Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants.

Secure Transfusion Solutions (STS) has received approval of its first Biologics License Application (BLA) from the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration (FDA).

Histogen Inc. announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA.

Deciphera Pharmaceuticals, Inc. announced findings of a planned exploratory analysis of data from the INTRIGUE Phase 3 clinical study of QINLOCK using circulating tumor DNA from a subgroup of patients with gastrointestinal stromal tumor previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only.